Cytomegalovirus Infections Clinical Trial
Official title:
Cytomegalovirus Glycoprotein B Genotypes in Israeli Patients: Relationship Between CMV Genotype, Clinical and Demographic Factors
The researchers select 100 cytomegalovirus (CMV) DNA samples from patients diagnosed with CMV infection. Patients include bone marrow transplant patients, pregnant women and newborns. The researchers determine viral load by real-time polymerase chain reaction (PCR). They amplify CMV-gB sequences by PCR and type by sequencing and restriction fragment length polymorphism (RFLP). The researchers obtain clinical data from patients' records. They examine association between patients' clinical status and CMV-gB genotype and viral load.
The study aims at finding association between CMV viral load and viral glycoprotein B
genotype and the clinical status of patients suffering from CMV infection. Bone marrow
transplant patients are at increased risk of developing severe CMV disease and are routinely
followed for viral load. Fetuses are also at high risk for developing severe malformations
and neurological defects following maternal primary infection during pregnancy. Therefore
amniotic fluid from women diagnosed with CMV infection is examined for CMV presence.
Newborns having congenital defects are tested for CMV excretion.
There is not yet any confirmed marker for assessment of the potential severity of the viral
infection and for prognosis. Therefore we shall attempt to find association between the
viral load and genotype and the clinical status.
CMV DNA samples prepared at the Central Virology Laboratory from clinical specimens obtained
from patients for diagnostic purposes will be coded and then subjected to viral load
analysis using real-time PCR. The gB genotype will be determined by either of two methods
described in the literature: (a) PCR and RFLP (b) PCR and sequencing.
Relevant clinical data will be retrieved from the patients clinical records and saved as
coded information to match the samples. Bone marrow transplant patients will be followed for
prolonged periods covering repeated viral reactivation events. Clinical records from mothers
and newborns will be matched when present. Otherwise maternal and newborn samples will be
kept as is.
Statistical analysis will be performed to try and find association between the clinical
status of patients, the viral load and the viral genotype.
;
Observational Model: Natural History, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03950414 -
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
|
Phase 1 | |
Recruiting |
NCT04690933 -
AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients
|
||
Withdrawn |
NCT04936971 -
Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response
|
Phase 4 | |
Recruiting |
NCT02671318 -
Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence
|
Phase 4 | |
Completed |
NCT01325636 -
Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirus
|
Phase 1/Phase 2 | |
Completed |
NCT00031421 -
Neonatal CMV-Ganciclovir Follow-up Study
|
N/A | |
Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
Terminated |
NCT03262194 -
Relevance of Gastric Aspirate in HCMV Detection
|
||
Completed |
NCT04478474 -
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
|
||
Recruiting |
NCT05370976 -
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation.
|
Phase 2 | |
Active, not recruiting |
NCT02943057 -
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis
|
Phase 4 | |
Completed |
NCT02538172 -
Cell-mediated Immunity for Prevention of CMV Disease
|
N/A | |
Completed |
NCT02642822 -
The Epidemiologic Study of Human Cytomegalovirus(CMV) in Female Students of Xiamen University
|
N/A | |
Completed |
NCT02134184 -
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
|
Phase 4 | |
Completed |
NCT00673868 -
Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants
|
Phase 1 | |
Active, not recruiting |
NCT05089630 -
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
Completed |
NCT01986010 -
Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)
|
Phase 1 | |
Recruiting |
NCT06145178 -
A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants
|
Phase 1 |